BACKGROUND AND AIM OF THE WORK: The purpose of our study was to determine whether highly active antiretroviral therapy (HAART) reduces the onset of cervical intraepithelial neoplasia (CIN) in HIV-positive women. METHODS: The study was designed to assess CIN incidence in a cohort of 101 HIV-positive women and to evaluate its relationship with ongoing antiretroviral therapy. The patients were screened through a combined Pap smear and colposcopic examination on a yearly basis. If any abnormalities were reported, the patients underwent targeted biopsy with histological confirmation of the diagnosis. RESULTS: During the follow-up period, 38 patients (37.6%) developed histologically verified CIN, including low-grade CIN in seven patients (6.9%) and high-grade CIN in 31 patients (30.4%). Over the study period, 43 patients (42.6%) were treated with HAART for at least 6 months, the average duration of treatment being 37 months. Analysis of HAART efficacy in preventing CIN onset, determined by the Cox regression model with a time-dependent covariate adjusted for the CD4 level at the first visit, showed that HAART significantly reduced the risk of developing CIN (hazard ratio, 0.3; p = 0.004). CONCLUSION: HIV-positive patients present a high incidence of CIN and of high-grade CIN in particular. HAART exhibits a protective action against the onset of cervical lesions.
BACKGROUND AND AIM OF THE WORK: The purpose of our study was to determine whether highly active antiretroviral therapy (HAART) reduces the onset of cervical intraepithelial neoplasia (CIN) in HIV-positive women. METHODS: The study was designed to assess CIN incidence in a cohort of 101 HIV-positive women and to evaluate its relationship with ongoing antiretroviral therapy. The patients were screened through a combined Pap smear and colposcopic examination on a yearly basis. If any abnormalities were reported, the patients underwent targeted biopsy with histological confirmation of the diagnosis. RESULTS: During the follow-up period, 38 patients (37.6%) developed histologically verified CIN, including low-grade CIN in seven patients (6.9%) and high-grade CIN in 31 patients (30.4%). Over the study period, 43 patients (42.6%) were treated with HAART for at least 6 months, the average duration of treatment being 37 months. Analysis of HAART efficacy in preventing CIN onset, determined by the Cox regression model with a time-dependent covariate adjusted for the CD4 level at the first visit, showed that HAART significantly reduced the risk of developing CIN (hazard ratio, 0.3; p = 0.004). CONCLUSION: HIV-positive patients present a high incidence of CIN and of high-grade CIN in particular. HAART exhibits a protective action against the onset of cervical lesions.
Authors: Megan J Huchko; Hannah Leslie; Jennifer Sneden; May Maloba; Naila Abdulrahim; Elizabeth A Bukusi; Craig R Cohen Journal: Int J Cancer Date: 2013-09-13 Impact factor: 7.396
Authors: Daniel Westreich; Naiomi Jamal; Jennifer S Smith; Doreen Schulze; Sophie Williams; Pam Michelow; Simon Levin; Cynthia Firnhaber Journal: Contraception Date: 2014-01-07 Impact factor: 3.375
Authors: David H Adler; Lisa Kakinami; Tebogo Modisenyane; Nkeko Tshabangu; Lerato Mohapi; Guy De Bruyn; Neil A Martinson; Tanvier Omar Journal: AIDS Date: 2012-08-24 Impact factor: 4.177
Authors: L Stewart Massad; Eric C Seaberg; D Heather Watts; Howard Minkoff; Alexandra M Levine; Donna Henry; Christine Colie; Teresa M Darragh; Nancy A Hessol Journal: Cancer Date: 2009-02-01 Impact factor: 6.860
Authors: Cynthia Firnhaber; Daniel Westreich; Doreen Schulze; Sophie Williams; Maureen Siminya; Pam Michelow; Simon Levin; Mark Faesen; Jennifer S Smith Journal: J Int AIDS Soc Date: 2012-06-07 Impact factor: 5.396